THALES
10.11.2021 09:02:05 CET | Business Wire | Press release
Building on the success of the CipherTrust Data Security Platform , Thales has released CipherTrust Intelligent Protection , a new solution that further simplifies operational complexity and strengthens data security efforts with automated processes that discover, protect and control sensitive data anywhere. Faced with overwhelming data growth, organisations can use CipherTrust Intelligent Protection to safeguard all sensitive information without the added cost and complexity of traditional data protection products and services. Once the sensitive data has been discovered and classified based on vulnerability and other risk profiles, the new solution automatically protects at-risk data with encryption and robust access controls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005012/en/
CipherTrust Intelligent Protection is a solution configuration within the Thales CipherTrust Data Security Platform that works together with CipherTrust Manager, CipherTrust Data Discovery and Classification, and CipherTrust Transparent Encryption –an all-in-one solution that delivers a unified approach. CipherTrust Intelligent Protection addresses the evolving challenges of regulatory compliance by facilitating accelerated time to compliance with automatic data protection controls. It also offers easy-to-use, pre-programmed tools to quickly and effectively secure unstructured sensitive data on-premises and in the cloud.
Reducing complexity in data protection with integrated automation
As organisations contend with expanding datasets, permanent work-from-home or hybrid office schemes, and the increased use of multi-cloud services, lack of visibility places their sensitive data at risk. Thales’s 2021 Data Threat Report
found that the use of cloud-based infrastructure exposes new risks as an organisation’s data footprint expands and raises concerns about operational complexity. Less than a quarter (24%) of respondents said they have complete knowledge of where their data is stored. Configurable policies with built-in templates to rapidly discover and classify unstructured sensitive data can be used to protect data on-premises and in the cloud.
“Cloud computing services and data security requirements will only grow more complex as organisations work to keep pace with new and evolving work environments,” said Todd Moore, VP Encryption Products at Thales. “Increased operational complexity demands simplified security procedures, and CipherTrust Intelligent Protection makes it significantly easier for companies to safeguard data proactively based on known vulnerabilities and data privacy regulations, which reduces overall business risk. Intelligent Protection provides the automation so customers can confidently take data security measures into their own hands with an all-in-one solution.”
Accelerating time-to-compliance
Today’s businesses and organisations must remain in compliance with a broad range of regulations and mandates, including GDPR, CCPA, HIPAA, and PCI DSS. Data privacy laws and regulations are never static – new ones appear regularly and existing ones often get enhanced, making it difficult for you to keep pace. An integrated and automated solution helps eliminate blind spots and human error, making a considerable difference in complying with various regulations.
"This all-in-one solution combines the best of the Ground Labs' data discovery technology with Thales’ CipherTrust Data Security Platform to give organizations the power to automatically discover, classify and keep sensitive data secure, whether it's on-premises or in the cloud," said Stephen Cavey, co-founder and chief evangelist of Ground Labs. “Our partnership with Thales underscores our common mission to protect our customers, regardless of where they store their data - and through this collaboration, we can better meet the data security needs of customers today and in the future."
“Managing risk is becoming increasingly burdensome for IT leaders not only because of the volume and sophistication of cyber-attacks but also due to the operational complexity of managing disparate security products and services,” said Frank Dickson, Program Vice President, Security & Trust, IDC . “Truly integrated platforms that automate the discovery, classification and protection of sensitive data can help organisations reduce both hard costs and risks associated with stitching together multivendor solutions while addressing and mitigating soft costs by simplifying data security operations and compliance.”
Uncover and Close Security Gaps
Finding a way to rapidly identify data compliance gaps and potential security risks is of paramount importance. Using the high performance and accurate discovery engine is an extremely useful way to find data subject to regulations that organizations may not realize even exists. CipherTrust Data Discovery and Classification provides risk-based guidance on what specific data to encrypt. Linking this discovery process to CipherTrust Transparent Encryption provides organizations with a fast track to automatically uncover and close security gaps.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
